| Texto completo | |
| Autor(es): |
de Oliveira, Mariana Gonsalves
;
Nadruz Jr, Wilson
;
Monica, Fabiola Zakia
Número total de Autores: 3
|
| Tipo de documento: | Artigo Científico |
| Fonte: | Biochemical Pharmacology; v. 205, p. 16-pg., 2022-11-01. |
| Resumo | |
The development of essential hypertension involves several factors. Vascular dysfunction, characterized by endothelial dysfunction, low-grade inflammation and structural remodeling, plays an important role in the initiation and maintenance of essential hypertension. Although the mechanistic pathways by which essential hypertension develops are poorly understood, several pharmacological classes available on the clinical settings improve blood pressure by interfering in the cardiac output and/or vascular function. This review is divided in two major sections. The first section depicts the major molecular pathways as renin angiotensin aldosterone system (RAAS), endothelin, nitric oxide signalling pathway and oxidative stress in the development of vascular dysfunction. The second section describes the role of some pharmacological classes such as i) RAAS inhibitors, ii) dual angiotensin receptor-neprilysin inhibitors, iii) endothelin-1 receptor antagonists, iv) soluble guanylate cyclase modulators, v) phosphodiesterase type 5 inhibitors and vi) sodium-glucose cotransporter 2 inhibitors in the context of hypertension. Some classes are already approved in the treatment of hypertension, but others are not yet approved. However, due to their potential benefits these classes were included. (AU) | |
| Processo FAPESP: | 18/09765-3 - Disfunção miccional e prostática em ratos de meia-idade e camundongos obesos: enfoque na NADPH oxidase (NOx) |
| Beneficiário: | Mariana Gonçalves de Oliveira Taranto |
| Modalidade de apoio: | Bolsas no Brasil - Pós-Doutorado |